GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanxi C&Y Pharmaceutical Group Co Ltd (SZSE:300254) » Definitions » Equity-to-Asset

Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) Equity-to-Asset : 0.42 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Shanxi C&Y Pharmaceutical Group Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Shanxi C&Y Pharmaceutical Group Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥618.4 Mil. Shanxi C&Y Pharmaceutical Group Co's Total Assets for the quarter that ended in Mar. 2024 was ¥1,476.2 Mil. Therefore, Shanxi C&Y Pharmaceutical Group Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.42.

The historical rank and industry rank for Shanxi C&Y Pharmaceutical Group Co's Equity-to-Asset or its related term are showing as below:

SZSE:300254' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33   Med: 0.53   Max: 0.66
Current: 0.42

During the past 13 years, the highest Equity to Asset Ratio of Shanxi C&Y Pharmaceutical Group Co was 0.66. The lowest was 0.33. And the median was 0.53.

SZSE:300254's Equity-to-Asset is ranked worse than
69.15% of 1086 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs SZSE:300254: 0.42

Shanxi C&Y Pharmaceutical Group Co Equity-to-Asset Historical Data

The historical data trend for Shanxi C&Y Pharmaceutical Group Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanxi C&Y Pharmaceutical Group Co Equity-to-Asset Chart

Shanxi C&Y Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.38 0.39 0.36 0.42

Shanxi C&Y Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.33 0.38 0.42 0.42

Competitive Comparison of Shanxi C&Y Pharmaceutical Group Co's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Shanxi C&Y Pharmaceutical Group Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanxi C&Y Pharmaceutical Group Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanxi C&Y Pharmaceutical Group Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Shanxi C&Y Pharmaceutical Group Co's Equity-to-Asset falls into.



Shanxi C&Y Pharmaceutical Group Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Shanxi C&Y Pharmaceutical Group Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=600.133/1433.075
=0.42

Shanxi C&Y Pharmaceutical Group Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=618.417/1476.234
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanxi C&Y Pharmaceutical Group Co  (SZSE:300254) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Shanxi C&Y Pharmaceutical Group Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Shanxi C&Y Pharmaceutical Group Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) Business Description

Traded in Other Exchanges
N/A
Address
No.53, Hubin Street, Economic and Technological Development Zone, Datong, CHN, 037010
Shanxi C&Y Pharmaceutical Group Co Ltd is engaged in the production, research and development, and sales of pharmaceutical products. The company offers pregnancy products and services, anti-infective, and urinary health.
Executives
Zuo Xue Min Supervisors
Huang Le Qun Director
Zhang Zhen Biao Executives
Yu Jun Xian Directors, Directors, and Executives
Zhao Qun Director
Weng Zhan Guo Director
Geng Chun Feng Director
Pang Xiao Quan Supervisors
Zhong Hai Rong Directors, executives
Xuan Hang Director

Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) Headlines

No Headlines